Evaluation of Human Papilloma Virus 16/18 Antibody Titer Seven Years after Vaccination with Cervarix among Adolescent Girls of Bangladesh

Chowdhury Shamima Sultana, S. Khatun, Sharif Masuma Ismat, M. Jahan
{"title":"Evaluation of Human Papilloma Virus 16/18 Antibody Titer Seven Years after Vaccination with Cervarix among Adolescent Girls of Bangladesh","authors":"Chowdhury Shamima Sultana, S. Khatun, Sharif Masuma Ismat, M. Jahan","doi":"10.3329/bjog.v34i2.58270","DOIUrl":null,"url":null,"abstract":"Background: Prevention of HPV infection by prophylactic vaccination is a critical step in reducing the cervical cancer burden. A pilot study was conducted to evaluate the serological immune response to the bHPV vaccine in adolescent Bangladeshi girls at 7th months of vaccination. This is the first in depth follow up study in Bangladesh to directly evaluate the long-term immunogenicity of the bHPV vaccine by measuring sustained HPV16/18 antibody titer seven years after vaccination. \nObjective: To determine the long-term immune response against HPV16/18 induced by the immunization with bivalent human papilloma virus (bHPV) 16/18 ASO4 adjuvanted vaccine by measuring the antigen specific antibody titer. \nMaterials & Method: This was a cross- sectional observational study conducted among 30 adolescent Bangladeshi girls from October 2015 to September 2016 who were vaccinated with 3 doses of bHPV vaccine from December 2008 to June 2009 in the Division of Gynaecological Oncology of BSMMU. Antibody titer against bHPV 16/18 ASO4 adjuvanted cervical cancer vaccine was measured in the serum of the 30 vaccinee in the Virology laboratory of BSMMU using DRG HPV IgG ELISA (REF.EIA- 4907) kit. Data were analyzed by using SPSS version 21. \nResults: The mean age of the population was 17.9±1.2 years. Among 30 vaccinated subjects, vaccine-induced long-term anti-HPV ELISA seropositivity was 93.33% (with 95% CI) for both HPV 16/18 types measured at year seven post-vaccination. Immunization with the HPV16/18 L1 virus-like particle vaccine adjuvanted with AS04 induced sustained high levels of antibodies among adolescent Bangladeshi girls against high-risk HPV genotypes 16/18. \nConclusion: Vaccination with bHPV is predicted to provide long-term protection against HPV infection and subsequent development of high-grade cervical lesions and cancer. \nBangladesh J Obstet Gynaecol, 2019; Vol. 34(2): 72-78","PeriodicalId":337805,"journal":{"name":"Bangladesh Journal of Obstetrics & Gynaecology","volume":"14 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Bangladesh Journal of Obstetrics & Gynaecology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3329/bjog.v34i2.58270","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Prevention of HPV infection by prophylactic vaccination is a critical step in reducing the cervical cancer burden. A pilot study was conducted to evaluate the serological immune response to the bHPV vaccine in adolescent Bangladeshi girls at 7th months of vaccination. This is the first in depth follow up study in Bangladesh to directly evaluate the long-term immunogenicity of the bHPV vaccine by measuring sustained HPV16/18 antibody titer seven years after vaccination. Objective: To determine the long-term immune response against HPV16/18 induced by the immunization with bivalent human papilloma virus (bHPV) 16/18 ASO4 adjuvanted vaccine by measuring the antigen specific antibody titer. Materials & Method: This was a cross- sectional observational study conducted among 30 adolescent Bangladeshi girls from October 2015 to September 2016 who were vaccinated with 3 doses of bHPV vaccine from December 2008 to June 2009 in the Division of Gynaecological Oncology of BSMMU. Antibody titer against bHPV 16/18 ASO4 adjuvanted cervical cancer vaccine was measured in the serum of the 30 vaccinee in the Virology laboratory of BSMMU using DRG HPV IgG ELISA (REF.EIA- 4907) kit. Data were analyzed by using SPSS version 21. Results: The mean age of the population was 17.9±1.2 years. Among 30 vaccinated subjects, vaccine-induced long-term anti-HPV ELISA seropositivity was 93.33% (with 95% CI) for both HPV 16/18 types measured at year seven post-vaccination. Immunization with the HPV16/18 L1 virus-like particle vaccine adjuvanted with AS04 induced sustained high levels of antibodies among adolescent Bangladeshi girls against high-risk HPV genotypes 16/18. Conclusion: Vaccination with bHPV is predicted to provide long-term protection against HPV infection and subsequent development of high-grade cervical lesions and cancer. Bangladesh J Obstet Gynaecol, 2019; Vol. 34(2): 72-78
孟加拉国少女接种Cervarix 7年后人乳头瘤病毒16/18抗体滴度的评价
背景:通过预防性接种预防HPV感染是减少宫颈癌负担的关键步骤。进行了一项试点研究,以评估孟加拉国青春期女孩接种bHPV疫苗第7个月时的血清学免疫反应。这是孟加拉国首次通过测量疫苗接种后7年持续的HPV16/18抗体滴度,直接评估bHPV疫苗的长期免疫原性的深入随访研究。目的:通过测定抗原特异性抗体滴度,观察二价人乳头瘤病毒(bHPV) 16/18 ASO4佐剂疫苗免疫对HPV16/18的长期免疫应答。材料与方法:这是一项横断面观察性研究,研究对象为30名孟加拉国少女,于2015年10月至2016年9月在BSMMU妇科肿瘤科接种了3剂bHPV疫苗,时间为2008年12月至2009年6月。采用DRG HPV IgG ELISA (refe . eia - 4907)试剂盒检测BSMMU病毒学实验室30例接种者血清中bHPV 16/18 ASO4佐剂宫颈癌疫苗的抗体滴度。数据分析采用SPSS 21版。结果:患者平均年龄17.9±1.2岁。在30名接种疫苗的受试者中,疫苗诱导的长期抗HPV ELISA血清阳性率为93.33% (95% CI),在接种疫苗后第7年检测HPV 16/18型。用AS04佐剂的HPV16/18 L1病毒样颗粒疫苗免疫,在孟加拉国青春期女孩中诱导了持续高水平的针对高危HPV基因型16/18的抗体。结论:预计接种bHPV疫苗可提供长期保护,防止HPV感染和随后发展为高级别宫颈病变和癌症。孟加拉国妇产科杂志,2019;Vol. 34(2): 72-78
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书